Therapeutic indications for the PolyPeptide Group pipeline projects 2020

PolyPeptide Group is proud to report double-digit growth for its pipeline projects.

PolyPeptide Group maintained a strong and healthy pipeline that has gained a significant growth in 2020. This growth in Pipeline Projects reflects the growth in peptide therapeutics market and emphasizes the importance of peptides in drug and vaccine development.

Double-digit growth in pipeline projects was driven by a wide variety of development programs including projects related to COVID-19 therapies and vaccines, as well as new projects focused on Oncology, and Cardiovascular & Metabolic Disorders, among others.

As a Global Leader in Peptide API Manufacturing & Development, the PolyPeptide Group is a trusted partner in several peptide-based projects aimed at therapies and vaccines for the COVID-19 pandemic.